ND, NF, SK, ES, and YK received support for medical writing, article processing charges, research funding, and advisory fees from Human Life CORD Japan Inc., related to the submitted work. ND received research funding from The Japan Agency for Medical Research and Development (AMED) (24ek0510039h0003), and a Grant-in-Aid for Scientific Research (KAKENHI) (23K06709); consulting fees from Janssen Pharmaceutical K.K.; and honoraria from AbbVie G.K., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. NF received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., MSD K.K., and Novartis Pharma K.K. SK received research funding from JSH Kanto-Koshinetsu district; honoraria from AbbVie G.K., Amgen K.K., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., SymBio Pharmaceuticals Ltd., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; and support for attending meetings from Pfizer Japan Inc., outside the submitted work. ES received research funding from Bristol-Myers Squibb K.K., The Japan Agency for Medical Research and Development (AMED) (23808509), and a Grant-in-Aid for Scientific Research (KAKENHI) (22K08471); honoraria from Amgen K.K., AbbVie G.K., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Nihon Servier Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ohara Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; fees for educational events from Kyowa Kirin Co., Ltd.; fees for advisory board participation from Bristol-Myers Squibb K.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ohara Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc.; and served as an unpaid vice director of the Japan Adult Leukemia Study Group (JALSG), outside the submitted work. YK received research funding from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Japan Blood Products Organization, Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Sumitomo Pharma Co., Ltd.; and honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K. GENOVA, Janssen Pharmaceutical K.K., Kowa Co., Ltd. Kyowa Kirin Co., Ltd., MSD K.K., Nikkei Visual Images, Inc., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Pharma Essentia Japan K.K., Research Organization of Information and Systems, PRECISION, R’s park Incorporated, Sanofi K.K., Sumitomo Pharma Co., Ltd., SymBio Pharmaceuticals Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. YK also serves as an Associate Editor for the International Journal of Hematology.